Drugs / MMF
last change Aug 2023 re-read 2 minutes ago

MMF

Developed for
nephritis · systemic lupus erythematosus

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT05686746 Comparator Jun 2022 → Jun 2023 nephritis, systemic lupus erythematosus Assiut University Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MMF ClinicalTrials.gov intervention name — accepted as the source's own label NCT05686746
Route Oral “1000 mg oral daily” NCT05686746